Therefore, IL-5 and its receptor appear to be proper therapeutic targets for biologic drugs (mepolizumab, reslizumab, benralizumab) that are able to inhibit eosinophilic inflammation and airway remodeling in both asthma and nasal polyposis [32]. This evidence concerns the gene IL5 and asthma.